Home > Insider Trading > Filing (0001144204-18-048704)

Filing Details

Accession Number:: 0001144204-18-048704
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-09-07 21:55:14
Reporting Period:: 2018-09-05

Accepted Time:: 2018-09-07 21:55:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175151	Cytosorbents Corp	CTSO	Surgical & Medical Instruments & Apparatus (3841)	980373793

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1442786	P. Phillip Chan	C/O Cytosorbents Corporation 7 Deer Park Drive, Suite K Monmouth Junction NJ 08852	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-09-05	600	$2.00	438,881	No	4	M	Direct
Common Stock	Acquisiton	2018-09-05	5,187	$2.10	444,068	No	4	M	Direct
Common Stock	Acquisiton	2018-09-06	2,900	$2.10	446,968	No	4	M	Direct
Common Stock	Acquisiton	2018-09-07	2,731	$2.10	449,699	No	4	M	Direct
Common Stock	Disposition	2018-09-05	600	$14.85	449,099	No	4	S	Direct
Common Stock	Disposition	2018-09-05	5,187	$14.85	443,912	No	4	S	Direct
Common Stock	Disposition	2018-09-06	2,900	$14.75	441,012	No	4	S	Direct
Common Stock	Disposition	2018-09-07	2,731	$14.11	438,281	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Statutory Stock Option (right to buy)	Acquisiton	2018-09-05	600	$0.00	600	$2.00
Common Stock	Non-Statutory Stock Option (right to buy)	Acquisiton	2018-09-05	5,187	$0.00	5,187	$2.10
Common Stock	Non-Statutory Stock Option (right to buy)	Acquisiton	2018-09-06	2,900	$0.00	2,900	$2.10
Common Stock	Non-Statutory Stock Option (right to buy)	Acquisiton	2018-09-07	2,731	$0.00	2,731	$2.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2008-12-31	2018-12-31	No	4	M	Direct
94,968		2019-01-08	No	4	M	Direct
92,068		2019-01-08	No	4	M	Direct
89,337		2019-01-08	No	4	M	Direct

Footnotes

Includes (i) the following restricted stock units (RSUs) that will be settled into common stock upon vesting upon a "Change In Control," as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 18,700 RSUs granted on February 24, 2017, (b) 57,000 RSUs granted on June 7, 2016, (c) 130,000 RSUs granted on April 8, 2015, and (d) 10,300 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 13,542 RSUs granted on February 24, 2017 which are unvested as of the date hereof, and (b) 28,667 RSUs granted on February 28, 2018 which are unvested as of the date hereof and (iii) shares of common stock owned by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.10 to $14.15, inclusive.
The option, representing a right to purchase a total of 100,155 shares, became exercisable per the following vesting schedule: fifty percent (50%) of the shares of common stock underlying the option vested on January 8, 2009, with the remaining fifty percent (50%) vesting at the discretion of the Issuer's Compensation Committee based on criteria including (but not limited to) success relative to (i) a timely completion of the Issuer's sepsis trial, (ii) raising capital for the Issuer, and (iii) partnering and business development; provided, however, that, in no event shall the vesting of all of the remaining fifty percent (50%) occur later than January 1, 2010.